Clinical outcomes of MAFLD versus NAFLD: A meta‐analysis of observational studies

Author:

Pennisi Grazia1,Infantino Giuseppe1,Celsa Ciro1,Di Maria Gabriele1ORCID,Enea Marco2,Vaccaro Marco2,Cannella Roberto3,Ciccioli Carlo1,La Mantia Claudia1,Mantovani Alessandro4ORCID,Mercurio Francesco1,Tilg Herbert5,Targher Giovanni67ORCID,Di Marco Vito1ORCID,Cammà Calogero1ORCID,Petta Salvatore1ORCID

Affiliation:

1. Section of Gastroenterology and Hepatology, Dipartimento Di Promozione Della Salute, Materno Infantile, Medicina Interna e Specialistica Di Eccellenza (PROMISE) University of Palermo Palermo Italy

2. Dipartimento di Scienze Economiche, Aziendali e Statistiche University of Palermo Palermo Italy

3. Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND) University of Palermo Palermo Italy

4. Department of Medicine, Section of Endocrinology, Diabetes, and Metabolism University of Verona Verona Italy

5. Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism Medical University Innsbruck Innsbruck Austria

6. Department of Medicine University of Verona Verona Italy

7. Metabolic Diseases Research Unit IRCCS Sacro Cuore—Don Calabria Hospital Negrar di Valpolicella Italy

Abstract

AbstractImportanceThe recent change in terminology from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction‐associated fatty liver disease (MAFLD) and metabolic dysfunction‐associated steatotic liver disease (MASLD) highlights the link between hepatic steatosis and metabolic dysfunction, taking out the stigmata of alcohol.ObjectiveWe compared the effects of NAFLD and MAFLD definitions on the risk of overall and cardiovascular (CV) mortality, liver‐related events (LRE), nonfatal CV events (CVE), chronic kidney disease (CKD), and extra‐hepatic cancers (EHC).Data Sources and Study SelectionWe systematically searched four large electronic databases for cohort studies (published through August 2023) that simultaneously used NAFLD and MAFLD definitions for examining the risk of mortality and adverse CV, renal, or oncological outcomes associated with both definitions. In total, 21 eligible cohort studies were identified. Meta‐analysis was performed using random‐effects modelling.ResultsCompared with those with NAFLD, individuals with MAFLD had significantly higher rates of overall mortality (random‐effect OR 1.12, 95% CI 1.04–1.21, p = .004) and CV mortality (random‐effect OR 1.15, 95% CI 1.04–1.26, p = .004), and a marginal trend towards higher rates of developing CKD (random‐effect OR 1.06, 95% CI 1.00–1.12, p = .058) and EHC events (random‐effect OR 1.11, 95% CI 1.00–1.23, p = .052). We found no significant differences in the risk LREs and nonfatal CVE between MAFLD and NAFLD. Meta‐regression analyses identified male sex and metabolic comorbidities as the strongest risk factors related to the risk of adverse clinical outcomes in MAFLD compared to NAFLD.Conclusions and RelevanceIndividuals with MAFLD have higher rates of overall and CV mortality and higher rates of developing CKD and EHC events than those with NAFLD, possibly due to the dysmetabolic risk profile related to MAFLD.

Funder

Ministero della Salute

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3